코그니션 테라퓨틱스, 알츠하이머 치료제 CT1812 임상 2상 결과 발표 - 효과 감소로 주가 43% 급락

Category

임상시험/파이프라인

Type

Conference

Official Announcement

https://www.globenewswire.com/news-release/2024/07/29/2920165/0/en/Cognition-Therapeutics-Proof-of-Concept-Phase-2-SHINE-Trial-Demonstrates-Consistent-Improvement-in-Cognitive-Outcomes-with-Once-Daily-Oral-CT1812-in-Mild-to-Moderate-Alzheimer-s-Pa.html

Firstword

https://firstwordpharma.com/story/5880077

Fierce Group

https://www.fiercebiotech.com/biotech/cognitions-phase-2-shine-data-tarnish-alzheimers-prospect

Release Date

2024/08/05

16 more properties

한글종합기사

Official Announcement

BioPharma Dive

BioSpace

Firstword

Fierce Group